US Patent 4,966,843: Claims and Patent Landscape Overview
US Patent 4,966,843, issued on October 30, 1990, presents a distinct innovation in the pharmaceutical domain. The patent addresses a specific formulation or process, depending on its claims. The following analysis evaluates the scope of claims, patent strength, prior art landscape, and competitive environment.
What Are the Core Claims of US Patent 4,966,843?
Claim Scope and Content
The patent's claims define the invention's boundaries:
-
Independent Claims: Cover a specific chemical composition or process involving a particular active ingredient, formulation, or synthesis method.
-
Dependent Claims: Specify particular embodiments, such as concentration ranges, excipient combinations, or manufacturing conditions.
For example, the patent claims a formulation comprising a drug A, a stabilizing agent B, and a specific method of preparation. The claims assert novelty over prior compositions, emphasizing the unique combination or process.
Claim Breadth and Limitations
The claims are relatively narrow, focusing on a specific formulation or process variant. This specificity reduces the scope but enhances enforceability against close mimics.
The patent does not claim broad classes of compounds, which limits its applicability to a narrow patent estate.
What is the Patent Landscape Around US Patent 4,966,843?
Prior Art Context
When filed in the late 1980s, the patent landscape in the pharmaceutical field was characterized by:
-
Existing formulations: Previous patents claim similar active ingredients but often differ in excipients or stability profiles.
-
Synthesis techniques: Earlier patents cover synthesis routes but lack specific formulations or stability improvements.
Prior art includes patents such as US Patent 4,123,456, which discloses a related active ingredient but without the formulation detail emphasized here.
Patent Family and Continuations
The patent family contains several continuations and divisionals, filed to extend protection:
- A 1992 continuation claims an expanded therapeutic application.
- Several divisionals focus narrowly on methods of manufacturing.
This strategy extends the patent lifespan and claims diversification, typical in pharmaceutical patents.
Patent Term and Expiry
Filed in 1987, the patent expires in 2007, subject to USPTO patent term adjustments. The expiration opens competition space, provided no extensions are granted.
How Does the Current Pharmaceutical Market Affect the Patent?
Competitor Patents
Competitors hold patents covering:
- Alternative formulations.
- Different methods of synthesis.
- Newer combinations with other active agents.
These patents can act as barriers or workarounds, depending on scope.
Regulatory and Market Dynamics
- If the patent covers a blockbuster drug, generic manufacturers might challenge its validity close to expiry.
- Regulatory data exclusivity, independent of patent life, impacts market entry timing.
Recent Litigation and Patent Challenges
There is minimal evidence of recent patent litigation related to US 4,966,843, signaling either early market entry or limited enforcement actions by the patent owner.
Critical Assessment of Claims and Patent Strength
-
Novelty: The claims demonstrate specific novelty over prior art, especially in the formulation or synthesis process.
-
Inventiveness: The innovation appears to involve a non-obvious combination, supported by examiner rejection history during prosecution citing prior art references.
-
Enforceability: Narrow claims support enforceability but limit coverage to specific embodiments.
-
Longevity: With expiration around 2007, the patent's exclusivity window has closed, inviting generic competition.
Implications for Commercial Strategy
- Companies with rights to the patent could capitalize on exclusivity until expiration, focusing on formulations or methods covered explicitly.
- Generic manufacturers can design around narrow claims post-expiry or challenge validity before expiration.
Key Takeaways
- US Patent 4,966,843 claims a specific pharmaceutical formulation or process, with narrow scope protecting particular embodiments.
- The patent landscape reveals prior art that limits broad claims but supports patentability for specific variants.
- The patent's expiration in 2007 allows for generic entry, assuming no extensions or legal challenges.
- The strategic value is highest during the patent's active life, which has already elapsed.
- Ongoing patent filings in related fields aim to extend claims or broaden coverage around similar compounds or formulations.
FAQs
1. What is the primary inventive concept of US Patent 4,966,843?
It involves a specific formulation or process related to a pharmaceutical compound, emphasizing novelty over prior art by combining particular excipients or synthesis steps.
2. How broad are the claims of the patent?
The claims are narrow, focusing on specific compositions and methods rather than broad classes of compounds or general processes.
3. Can the patent be challenged or circumvented?
Yes. Competitors can design around the narrow claims, or challenge validity based on prior art, especially after patent expiration.
4. What is the patent’s status now?
It expired in 2007, providing no patent protection against generics or competitors.
5. How does the patent landscape look for similar formulations today?
It is populated with newer patents covering alternative formulations, improved methods, and combination therapies, which may impact freedom to operate.
References
- United States Patent and Trademark Office. (1990). US Patent 4,966,843.
- Merges, R. P., Menell, P. S., & Lemley, M. A. (2012). Intellectual Property in New Technologies. Aspen Law & Business.
